Post Exposure Post Exposure Prophylaxis Prophylaxis (PEP/oPEP) (PEP/oPEP) Dr Don Ajith Karawita Dr Don Ajith Karawita MBBS (PERA), PgD Ven (COL), MD Venereology MBBS (PERA), PgD Ven (COL), MD Venereology (COL) (COL) (Senior Registrar in Venereology) (Senior Registrar in Venereology) National STD/AIDS Control Programme National STD/AIDS Control Programme
59
Embed
Post Exposure Prophylaxis (PEP/oPEP) Dr Don Ajith Karawita MBBS (PERA), PgD Ven (COL), MD Venereology (COL) (Senior Registrar in Venereology) National.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Post Exposure Prophylaxis Post Exposure Prophylaxis (PEP/oPEP)(PEP/oPEP)
Dr Don Ajith Karawita Dr Don Ajith Karawita MBBS (PERA), PgD Ven (COL), MD Venereology (COL)MBBS (PERA), PgD Ven (COL), MD Venereology (COL)
(Senior Registrar in Venereology)(Senior Registrar in Venereology)
National STD/AIDS Control Programme National STD/AIDS Control Programme
CDC Guidelines 2001.CDC Guidelines 2001.
CDC CDC headquarters headquarters in Atlantain Atlanta
4. Pharmaceutical waste (Returned to supplier/ MSD)
5. Radioactive waste (Keep for radioactive decay→Dispose as non hazardous waste)
1. Sharps
Dispose to common
garbage site/bin
Collected by local authorities
Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human Immunodeficiency Virus (HIV)and Human Immunodeficiency Virus (HIV)
• Bloodborne viruses
• Can produce chronic infection
• Transmissible in healthcare settings
• Data from multiple sources (e.g., surveillance, observational studies, serosurveys) used to assess risk of occupational transmission
Risk of Bloodborne Virus Transmission after Risk of Bloodborne Virus Transmission after Occupational Percutaneous ExposureOccupational Percutaneous Exposure
Step 1Step 1 Provide immediate care to the Provide immediate care to the exposure siteexposure site
• Post exposure Wound Management:Post exposure Wound Management: – Wash wounds and skin with soap and water– Flush mucous membranes with water– No evidence of benefit for:
• application of antiseptics or disinfectants• squeezing (“milking”) puncture sites
• Avoid use of bleach and other agents caustic to skin
• Inform authorities → Infection control unit.
Management of sharps accidentsManagement of sharps accidents
WHO / SEAR 1999
WHO / SEAR 1999
Elements of Postexposure Management
• Wound management & Exposure reporting → Step 1
• Risk Assessment → Step 2– (1) blood borne infection status of source source
Vaccination and antibody response status of exposed
worker*
Treatment when source is found to be:
HBsAg positiveHBsAg negative
Source unknown
or not available
for testing
Unvaccinated HBIG x1 and initiate Hepatitis B vaccine series.
Initiate hepatitis B vaccine series
Initiate hepatitis B vaccine series
Previously vaccinated
Known responder No treatment No treat. No treatment
Known non-responder
HBIGx1 and initiate re-vaccination or HBIGx2
No treatment
If known high risk source, treat as if source were HBsAg positive
Antibody response unknown
Test exposed person for anti-HBs
1. If adequate, no treatment.
2. If inadequate, HBIGx1 and vaccine booster.
No treatment
Test exposed person for
anti-HBs: 1. If adequate,
no Treatment
2. If inadequate, vaccine
booster and recheck titer
in 1-2 months.
• Persons who have previously been infected with HBV are immune to reinfection and do not require PEP.
• Hepatitis B immunoglobulin: dose 0.06ml/kg im• A responder is a person with adequate levels of serum
antibody to HBsAg (i.e. anti-HBs > 10mIU/ml): a non-responder is a person with inadequate response to vaccination (i.e. serum anti-HBs antibody< 10mIU/ml)
• The option of giving one dose of HBIG and reinitiating the vaccine series is preferred for non-responders who have not completed a second 3-dose vaccine series. For those who previously completed a second vaccine series but failed to respond, 2doses of HBIG are preferred. Give one dose at time of exposure, and the second dose one month later.
Regimen Prevention of HBV Infection
Multiple doses of HBIG alone when 1st dose initiated within 1 week
70-75%
Hepatitis B vaccine series alone 70-75%
Combination of HBIG and vaccine series 85-95%
* Estimated for adults, based on perinatal data
Efficacy of HBV PEP*
Hepatitis B Vaccine: Long-Term Efficacy
• Anti-HBs titers decline to <10 mIU/mL in 30-50% of adults within 8-10 years after vaccination
• Exposure to HBV results in anamnestic anti-HBs response that prevents clinically significant HBV infection
• Immune memory remains intact for at least 20 years after immunization
• Chronic HBV infection rarely documented among vaccine responders
• Booster doses currently not recommended
oPEPoPEPHepatitis C Hepatitis C InfectionInfection
oPEPoPEPHepatitis C InfectionHepatitis C Infection
Not recommendedNot recommended
oPEPHIV Infection
AIDS
Clinical stage 4
AIDS Defining illnesses
Overview of the HIV clinical disease
75%Clinical stage 2
Clinical stage 3
Clinical stage 1
8 to 12 years1-4wks 3wks
HIV Seroconversio
n illness
33%
Natural History of HIV Infection
Percutaneous injuries
Exposure type
Infection status of the sourceHIV-positive, class 1
Aymptomatic HIV infection or known low viral load (e.g. <1500)
HIV-positive, class 2
Symptomatic HIV infection, AIDS, Acute seroconversion, or known high viral load
Source of unknown HIV status
(e.g deceased source person with no samples available for HIV testing)
Unknown source
(e.g. a needle from a sharps disposal container)
HIV negative
Less severe (e.g. solid needle, superficial injury)
Recommend basic 2-drug PEP
Recommend expanded 3-drug PEP.
Generally, no PEP
Generally, no PEP
No PEP
More severe
(e.g. large-bore hollow needle, deep puncture, visible blood on device or needle used in patient’s artery or vein)
Recommend expanded 3-drug PEP.
Recommend expanded 3-drug PEP.
Generally, no PEP
Generally, no PEP
No PEP
Mucous membrane exposures and non-intact skin exposures.
Exposure type
Infection status of the source
HIV-positive, class 1
Asymptomatic HIV infection or known low viral load (e.g. <1500)
HIV-positive, class 2
Symptomatic HIV infection, AIDS, acute seroconversion, or known high viral load
Source of unknown HIV status
(e.g. deceased source person with no samples available for HIV testing)
Unknown source
(e.g. splash from inappropriately disposed blood)
HIV-Negative
Small volume (e.g. few drops)
Consider basic 2-drug PEP
Recommend basic 2-drug PEP
Generally, No PEP
Generally, No PEP
No PEP
Large volume (e.g. major blood splash)
Recommend basic 2-drug PEP
Recommend expanded 3-drug PEP
Generally, No PEP
Generally, No PEP
No PEP
• If drug resistance is a concern, obtain expert consultation. Initiation of PEP should not be delayed pending expert consultation and, because expert consultation alone cannot substitute for face-to-face counseling, resource should be available to provide immediate evaluation and follow-up care for all exposures.
• The designation “consider PEP” indicates that PEP is optional and should be based on as individualized decision between the exposed person and the treating clinician. However, consider basic 2-drug PEP for a source with HIV risk factors, or occurs in a setting where exposure to HIV-infected persons is likely.
• If PEP is offered and taken, and the source is later determined to be HIV negative, PEP should be discontinued.
• For skin exposures, follow-up is indicated only if there is evidence of compromised skin integrity (e.g. dermatitis, abrasion, or open wound)
Risk of Adverse Effects
Risk of Transmission
Considerations When Using PEP Considerations When Using PEP
PEP
Basic Regimen
Zidovudine (ZDV)
Lamivudine (3TC)
200 mg tid (300 mg PO bid)
150 mg bid
Alternate Basic Regimens
Didanosine (ddI)
Stavudine (d4T)
Stavudine (d4T) Lamivudine (3TC)
200 mg bid (125 mg bid if <60 kg)
40 mg bid (30 mg bid if <60 kg)
40 mg bid (30 mg bid if <60 kg)
150 mg bid
Postexposure Management: HIV PEP Postexposure Management: HIV PEP Basic RegimenBasic Regimen
Expanded Regimen
Basic regimen plus one of the following
Indinavir (IDV) 800 mg q8h
Nelfinavir (NFV) 750 mg tid or 1250 mg bid
Efavirenz (EFV) 600 mg daily
Abacavir (ABC) 300 mg bid
Postexposure Management: HIV Postexposure Management: HIV Expanded RegimenExpanded Regimen
Elements of Postexposure Management
• Wound management & Exposure reporting → Step 1
• Risk Assessment → Step 2– (1) blood borne infection status of source source
HBV Infection HCV infection HIV InfectionAdvice exposed persons to seek medical evaluation for any acute any acute illnessillness occurring during follow-up
Advice exposed persons to seek medical evaluation for any acute any acute illnessillness occurring during follow-up
Perform HIV antibody testing for illness compatible with an acute acute retroviral syndrome.retroviral syndrome.
Test for anti-HBs 1-2 months after last dose of vaccine if only if only vaccine vaccine given. given. ((anti-HBsanti-HBs response to vaccine cannot be ascertained if HBIG received in the previous 3-4 months)
Perform testing for anti-HCV and ALT 4-6 months after exposure
Evaluate exposed persons taking PEP within 72 hours after exposure and monitor for drug toxicity for at least 2 weeks.
Follow-up not indicated if exposed person immune to HBV or received HBIG PEP
Perform HCV RNA testing at 4-6 weeks if earlier diagnosis of HCV infection desired
Perform HIV-antibody testing for at least 6 months postexposure (e.g. at baseline, 6 weeks, 3 months, and 6 months)
Prevent secondary transmissionrevent secondary transmission on during the follow-up period. Refrain from donating blood, plasma, organs, tissue, or semen.
No need for: modification of sexual practices or patient care, refraining from conception
Confirm repeatedly reactive anti-HCV EIA with supplemental test
Prevent secondary Prevent secondary transmissiontransmission on during the follow-up period.
Step 4 Perform follow up testing and provide counselingStep 4 Perform follow up testing and provide counseling
Preventing Transmission of Preventing Transmission of Blood borne VirusesBlood borne Viruses
in Healthcare Settingsin Healthcare Settings
Frequency of Percutaneous Injury in Frequency of Percutaneous Injury in Healthcare PersonnelHealthcare Personnel
• Based on CDC estimates, 384,325 (95% CI 311,091-463,922) percutaneous injuries are sustained by healthcare personnel in US hospitals annually*
• The number of injuries sustained outside of hospital settings is unknown
• Frequency of percutaneous injury varies by occupational group and healthcare setting
* Panlilio, AL, et. al. Estimate of the Annual Number of Percutaneous Injuries in U.S. Healthcare Workers. 4th Decennial Conference, March 5-9, 2000
Preventing Transmission of Bloodborne VirusesPreventing Transmission of Bloodborne Virusesin Healthcare Settingsin Healthcare Settings
• Promote hepatitis B vaccination• Treat all patients as potentially